DealBook Column: The Election Won't Solve All Puzzles

Here comes more uncertainty.

It may sound counterintuitive, but whatever the outcome of the election — whether President Obama or Mitt Romney wins — the economy and markets are likely to face more uncertainty, not less, over the coming year.

“Uncertainty” has become the watchword over the last several years for many chief executives, politicians and economists as an explanation — or perhaps an excuse — for the economy’s slow growth, for the lack of hiring by business and for the volatility in the stock market.

“The claim is that businesses and households are uncertain about future taxes, spending levels, regulations, health care reform and interest rates. In turn, this uncertainty leads them to postpone spending on investment and consumption goods and to slow hiring, impeding the recovery,” a group of professors from Stanford University and the University of Chicago wrote in a study that found “current levels of economic policy uncertainty are at extremely elevated levels compared to recent history.” (The professors have created a Web site, policyuncertainty.com, where you can track the “uncertainty” levels.)

Come Wednesday morning, we should know who our president will be. But the uncertainty hardly ends there.

Almost immediately after the elections, the next big talking point on Wall Street and in Washington is going to be the now infamous “fiscal cliff,” a series of automatic tax increases and spending cuts that was the result of a Congressional compromise reached last summer and is to take effect on Jan. 1, unless Congress finds an alternative. Some economists say the tax increases and spending cuts in the existing agreement could shave as much as 4 percent off G.D.P. if they are not renegotiated. Already, executives say that the uncertainty over the outcome of the fiscal cliff is causing them to hold back from making new investments.

But the greatest likelihood is that the fiscal cliff isn’t going to be resolved soon at all —the betting line of the political cognoscenti is that no matter who wins, Congress will find a way to kick the issue down the road, perhaps as far as the fall of 2013, providing a new cloud of uncertainty over the economy.

For investors, the fiscal cliff includes a tax increase on dividends (making them the equivalent of ordinary income, on which rates could rise to as high as 39.6 percent) and capital gains (up to 20 percent from 15 percent). In a note to clients sent out on Sunday night, Goldman Sachs said that it expected the rate for both dividends and capital gains to be negotiated to 20 percent in either a second Obama term or a Romney presidency. But more important, Goldman noted that when similar tax increases were on the table in 1970 and 1986, “the S.& P. 500 posted negative returns in the December prior to implementation as investors locked in the lower rate.” December, the report said, “has the second-highest average monthly return” since 1928.

Many investors have already begun selling stocks and companies in anticipation of tax increases. Speculation was rampant last week that one of the reasons for the timing of the sale of George Lucas’s company, Lucasfilm, to Disney for $4.1 billion in cash and stock, was the impending changes in tax policy. (Mr. Lucas has said that he plans to donate a majority of his wealth to charity.)

Once we get past the fiscal cliff, if we do at all, there is Europe. Remember Europe? The issues in Greece and Spain have managed to stay off the front pages during the election run-up, but they have not gone away. Some economists have argued that things have gotten worse. Angela Merkel, the chancellor of Germany, who will face election in 2013, said on Monday that the fiscal crisis in Europe was likely to last at least five years. “Whoever thinks this can be fixed in one or two years is wrong,” she said.

And don’t forget the Middle East. That “uncertainty” for the world — and the global economy — isn’t going away anytime soon either. Questions about a possible attack on Iran will persist under either candidate.

And finally, there is Ben Bernanke, chairman of the Federal Reserve, one of the biggest uncertainties of them all. As I reported in this column two weeks ago, the greatest likelihood is that Mr. Bernanke will step down at the end of his term in early 2014 no matter who wins the election.

It’s possible — though unlikely — that his departure could happen even sooner if Mr. Romney wins. Over the next year and a half, Mr. Bernanke’s future as the Fed chairman will feed a sense of uncertainty among investors who have become accustomed to his easy money policies. If President Obama wins, he is likely to appoint a successor to Mr. Bernanke who is dovish on monetary policy, and more likely to keep printing money as Mr. Bernanke has, a strategy that comes with its own risks. If Mr. Romney wins, he may appoint a more hawkish chairman, a move that could create a different sense of uncertainty about how the Federal Reserve will unwind itself from Mr. Bernanke’s policies.

None of these issues are new. President Obama took office facing a fiscal policy dispute that was not and probably could not be settled given the gridlock in Congress. No solution is in sight for Europe’s problems. Tension in the Middle East is escalating as fast as nuclear technology. And the Federal Reserve’s monetary policy is at its most opaque since the Reagan administration.

All of which shows that the comedian Jon Stewart is more on target than ever with the cheeky title of his election coverage on “The Daily Show” on Comedy Central. Carrying on a tradition, it is known as “Indecision 2012.”

Update that to 2013, and it’s good for another year.

Read More..

State Supreme Court wants Arizona donors audited









SACRAMENTO — An Arizona group was scrambling late Sunday to keep secret the individuals behind its $11-million donation to a California campaign fund after California's Supreme Court, in a rare and dramatic weekend action, ordered it to turn over records that could identify the donors.

The order followed days of frenzied legal battles between California regulators, who have tried to get documents related to the anonymous contribution before election day, and attorneys for the Arizona nonprofit who have resisted delivering them.

The showdown continued into the night Sunday, with no records produced nearly seven hours after the justices' late-afternoon deadline. Lawyers for the nonprofit said they were trying to comply even as they rushed to ask the U.S. Supreme Court to halt to the audit.





The $11 million went to a committee that is fighting tax increases proposed by Gov. Jerry Brown in Proposition 30 and promoting an initiative that could limit political spending by unions, Proposition 32. The donation has been among the most controversial moves of this election season, with Brown railing against the "shadowy" contributors at campaign appearances.

The case, which has the potential to reshape a growing sector of political giving, has put California at the forefront of a national debate over concealed political donations. Ann Ravel, chairwoman of the state Fair Political Practices Commission, which initially sued the Arizona group, called the California high court's decision historic.

It all began with a complaint from activists at Common Cause, who said the $11-million donation from Americans for Responsible Leadership violated a new California regulation. Federal law allows nonprofits to keep the identities of their donors confidential, but a rule implemented here in May says contributors must be identified if they give to nonprofits with the intention of spending money on state campaigns.

The matter has rocketed from court to court as Ravel's commission fought to obtain the Arizona group's records. The seven justices of the state Supreme Court, based in San Francisco, made the unusual decision to consider the matter over the weekend. On Sunday afternoon, they held a conference call to discuss it.

Shortly after 3 p.m., they ordered Americans for Responsible Leadership to produce — in less than an hour — the records sought by Ravel, a Brown appointee. The justices did not explain their unanimous decision, indicating in their order that they would consider the legal issues in a later, more detailed ruling.

But no records were delivered as a team of auditors and lawyers waited in the commission's Sacramento office, prepared to dig into the nonprofit's emails, text messages, financial statements and meeting minutes. Their task would be to comb the disclosures for any sign that the contribution violated the new California regulation.

If the Arizona group was found to be in violation, the state planned to direct the nonprofit to disclose the donor names and was ready to back up the directive by seeking another court order, if needed, Ravel said.

Lawyers for Americans for Responsible Leadership balked at the California court's order, preferring to ask the U.S. Supreme Court to weigh in on the case before turning over anything. In the early evening, they asked the California jurists for more time — at least until 9 a.m. Monday — to comply.

That would provide enough time, they said, to request an emergency stay from the nation's high court. Attorneys defending the nonprofit group wrote to Washington outlining their case.

"Disclosure in this highly charged political environment and in the face of an unprecedented and vehemently legally contested investigation is impermissible viewpoint discrimination and plainly violative of ARL's First Amendment rights," Thad Davis, a lawyer for the nonprofit, said in his letter to the U.S. Supreme Court.

Justice Anthony Kennedy has authority over Western states and can issue a stay in this case.

Meanwhile, the state court told the Arizona group there would be no extension.

At risk of being in contempt of the state court, lawyers for the nonprofit said they would begin an "attempt to comply with the order."

"While we are working to deliver the records, we still believe the FPPC does not have the authority to take such an action," said Matt Ross, a spokesman for the group's legal team, in a statement Sunday night.

Ravel said she had staff members prepared to work all night to review whatever the Arizona group produced.

A career government lawyer, Ravel is hardly known in Sacramento as a firebrand. But the Arizona group says in its court filings that she is conducting a "one-woman media onslaught, rabblerousing and prejudging, including 'tweeting' her incendiary view."

State authorities are keeping the pressure on as election day looms.

California Atty. Gen. Kamala Harris, whose office is helping to represent the Fair Political Practices Commission in court, said in an interview that the Arizona group's legal maneuvers are "an effort to obstruct the process and run out the clock."

chris.megerian@latimes.com

maura.dolan@latimes.com

Times staff writer Evan Halper contributed to this report.





Read More..

A Google-a-Day Puzzle for Nov. 5














Our good friends at Google run a daily puzzle challenge and asked us to help get them out to the geeky masses. Each day’s puzzle will task your googling skills a little more, leading you to Google mastery. Each morning at 12:01 a.m. Eastern time you’ll see a new puzzle posted here.


SPOILER WARNING:
We leave the comments on so people can work together to find the answer. As such, if you want to figure it out all by yourself, DON’T READ THE COMMENTS!


Also, with the knowledge that because others may publish their answers before you do, if you want to be able to search for information without accidentally seeing the answer somewhere, you can use the Google-a-Day site’s search tool, which will automatically filter out published answers, to give you a spoiler-free experience.


And now, without further ado, we give you…


TODAY’S PUZZLE:



Note: Ad-blocking software may prevent display of the puzzle widget.




Ken is a husband and father from the San Francisco Bay Area, where he works as a civil engineer. He also wrote the NYT bestselling book "Geek Dad: Awesomely Geeky Projects for Dads and Kids to Share."

Read more by Ken Denmead

Follow @fitzwillie and @wiredgeekdad on Twitter.



Read More..

Katy Perry wears dress with Obama slogan at rally
















MILWAUKEE (AP) — Pop star Katy Perry is sporting a skin-tight minidress with President Barack Obama‘s campaign slogan “Forward” emblazoned across it at the president’s rally in Milwaukee.


Perry came on stage at Saturday’s event initially wearing a red, white and blue dress and holding a microphone shaped like the Statue of Liberty’s torch.













But after her first song, a cover of Al Green’s soul hit “Let’s Stay Together,” she tossed aside the dress to reveal the bright blue minidress.


Obama’s slogan “Forward” is also Wisconsin’s state motto.


Perry paused midway through her set to make a pitch for donations to victims of Superstorm Sandy.


Obama’s rally with Perry comes before he’s set to be in Madison on Monday with rocker Bruce Springsteen.


Entertainment News Headlines – Yahoo! News



Read More..

Chelation Therapy Shows Slight Benefit in Heart Disease Clinical Trial


LOS ANGELES — To the surprise of many cardiologists, a controversial alternative therapy proved beneficial to people with heart disease, reducing the rate of death and cardiovascular problems in a clinical trial, researchers said on Sunday.


The benefit of the treatment, known as chelation therapy, barely reached statistical significance, and there were questions about the reliability of the study. Even the investigators in the trial said the results were insufficient by themselves to justify recommending use of the treatment.


Still, the unexpected finding should provide some vindication to the National Institutes of Health for sponsoring the $30 million study, which was plagued by delays and problems.


“There may be a biological effect and that biological effect should be taken seriously,” and “pursued with additional research,” Dr. Gervasio A. Lamas of Mount Sinai Medical Center in Miami, the lead investigator, said at a news conference here at the annual scientific meeting of the American Heart Association.


Dr. Elliott Antman, representing the heart association, applauded the National Institutes of Health for sponsoring the study while also expressing caution. “Intriguing as these results are, they are unexpected and should not be interpreted as an indication to adopt chelation therapy into clinical practice,” said Dr. Antman, a cardiologist at Brigham and Women’s Hospital in Boston.


Chelation therapy involves the infusion of agents that remove metals from the bloodstream.


More than 100,000 Americans with heart disease undergo chelation therapy each year, at a cost of about $5,000 per course of treatment, experts here said. The hypothesis is that chelation can remove the calcium that is a contributor to arterial plaques.


But skeptics said there was not enough evidence backing chelation therapy to even begin a clinical trial. Proponents of the study said that since chelation therapy was already widely used, it should be subject to the same rigorous scientific testing used to study conventional pharmaceuticals.


And some skeptics were not persuaded at all. Dr. Steven Nissen, head of cardiovascular medicine at the Cleveland Clinic, said the study was “fatally flawed,” with many of the doctors involved being on the fringes of medicine and many patients dropping out of the trial. He said if people got the mistaken idea from the study that chelation was beneficial “it would be a public health catastrophe.”


The study, which began enrolling patients in 2003, was plagued by problems from the start. It fell way behind its goal of recruiting nearly 2,400 patients in three years. The trial was also suspended in 2008 for investigations by government agencies, one over conduct at trial sites and the other about whether patients were being adequately informed that chelation can cause death. The study was allowed to resume the next year, after some changes were made.


The trial ended up with 1,708 patients at 134 centers in the United States and Canada. The patients all had had previous heart attacks.


Half the patients received the chelation therapy, a synthetic amino acid called disodium ethylene diamine tetra acetic acid, or EDTA, as well as other substances. These were given by infusion every week for 30 weeks, followed by 10 more infusions at intervals of two to eight weeks. The other half received infusions of placebo.


After a follow-up of 55 months, 26 percent of those who received chelation therapy had died, suffered a heart attack or stroke, had a procedure to reopen a coronary artery or had been hospitalized for angina. That was less than the 30 percent for those who received a placebo, a difference that was barely statistically significant.


Doctors said there were reasons for caution.


Virtually all the of difference between the treatment and the placebo groups occurred in the third of patients who had diabetes. The placebo contained some sugar, which conceivably could have harmed the diabetics. Also, at least within the first two years, the chelation therapy did not improve physical functioning or psychological well being, according to surveys of the patients.


Dr. Mark A. Creager, a cardiologist at Brigham and Women’s Hospital who was not involved in the study, said the chelation infusion also contained a high dose of vitamin C and the blood thinner heparin. It could be that one of those ingredients, not the chelation agent, were responsible for any benefit, he said.


Dr. Lamas, the lead investigator, said the chelation treatment was well tolerated. But he said investigators did not yet know why some patients receiving the therapy dropped out of the trial.


Another study presented at the heart meeting on Sunday found coronary bypass surgery superior to the use of stents for patients with diabetes and multiple heart blockages.


The trial involved 1,900 patients followed for five yeas. About 27 percent of those who received stents either died or had a heart attack or stroke, compared with about 19 percent of those undergoing bypass surgery. There was an increase in stroke risk with surgery, but that was outweighed by fewer deaths and heart attacks.


Previous studies had already suggested that surgery was better for diabetic patients with severe coronary disease, and practice guidelines already say it is “reasonable” to choose surgery. But the new study, sponsored by the National Institutes of Health, shows the same result even using modern drug-covered stents.


About 700,000 Americans undergo artery opening procedures for more than one blood vessel each year, and about 25 percent of them have diabetes, according to the investigators.


The study results were also published online by the New England Journal of Medicine. Johnson & Johnson and Boston Scientific provided the stents used in the study.


Read More..